Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Hasbani Issued a Decision on the Regulation of Surgical Operations in Specialized Hospitals and Reminded Beauty Centers of the Legal Deadline Given until August to Settle their Situation

 
Deputy Prime Minister Health Minister Ghassan Hasbani held a press conference in his office at the Ministry of Public Health, Bir Hassan during which he tackled the organizational frames of beauty Centers and specialized hospitals.
He started by saying: “After the repetitive complaints received by the Ministry of Public Health on accidents and infringements occurring in the sector of Aesthetic Medicine, and as a result of what happened yesterday after the liposuction operation in a specialized hospital, we realized that it is our duty to inform you about the approach of the Ministry to the regulation of aesthetic sector and the actions taken and that being completed through regulatory actions."
 
Beauty Centers

He added: "The Ministry of Public Health followed up the work of the Parliamentary Health Commission for the regulation of Medical Beauty Centers licenses that resulted in the issuance of decision No. 30 of 10 February 2017, which was published in The Official gazette on February 16, 2017.  The Definition of Aesthetic Medicine, its centers and the medical work they are authorized to carry out are regulated by Law which has determined the medical specializations that have the right to hold a permission to practice the profession of Aesthetic medicine. According to the law, the existing Beauty Centers are given a 6 month period to regularize their legal situation as of the date of the publication of this law, i.e. 16 August 2017, under penalty of closing these centers by a decision of Health Minister.

Specialized Hospitals

Health Minister added that he has issued a regulatory decision for specialized hospitals related to the regulation of surgeries which stipulates the following:
  1. Surgeries that may cause complications that require intensive care like liposuction and other surgeries shall not be carried out in places other than specialized hospitals which include an intensive care division which holds a license form Health Ministry in accordance with due process.
  2. The doctor should explain to the patient the risks of the surgery, including the plastic surgery, and ask the patient to sign the Patient Right Form and the informed consent. 
Hasbani stressed that this decision will be immediately communicated to all concerned parties.

Death Case

Hasbani talked also about the recent tragic death of the woman who underwent a liposuction opertaion in a specialized hospital and said: “the Public Prosecution and the Syndicate of Physicians have launched investigations and the Ministry of Public Health has started to investigate and complete the files. The Committee of investigations will meet in the Ministry in order to consider the details of this case and provide consultancies to the Syndicate and Justice where needed.
    1
    ...
ATC Name B/G Ingredients Dosage Form Price
M02AX10 ALGESAL SURACTIVE B Salycilic acid - 6.54g/100g, Diethylamine - 3.46g/100g, Myrtecaine - 1g/100g Cream 1,006,538 L.L
L04AD02 ADVAGRAF B Tacrolimus monohydrate - 3mg 3mg Capsule, prolonged release 68,645,618 L.L
L04AD02 ADVAGRAF B Tacrolimus monohydrate - 1mg 1mg Capsule, prolonged release 25,729,044 L.L
A02AF02 ACTONORM B Aluminium hydroxide - 220mg/5ml, Magnesium hydroxide - 200mg/5ml, Simethicone - 25mg/5ml Suspension 403,153 L.L
L01ED03 ALECENSA B Alectinib - 150mg 150mg Capsule, hard L.L
D06BB10 ALDARA B Imiquimod - 5% 5% Cream 6,301,277 L.L
L04AD02 ADVAGRAF B Tacrolimus monohydrate - 5mg 5mg Capsule, prolonged release 85,485,667 L.L
L04AD02 ADVAGRAF B Tacrolimus monohydrate - 0.5mg 0.5mg Capsule, prolonged release 13,297,758 L.L
R03BB01 ATROVENT B Ipratropium bromide - 250mcg/2ml 250mcg/2ml Inhaltion solution with nebuliser 544,256 L.L
R03BB01 ATROVENT B Ipratropium bromide - 500mcg/2ml 500mcg/2ml Inhaltion solution with nebuliser 713,580 L.L
R03BB01 ATROVENT N B Ipratropium bromide - 20mcg/actuation 20mcg/actuation Inhalation aerosol metered dose 428,686 L.L
N06DA02 ARICEPT B Donepezil HCl - 5mg 5mg Tablet, film coated 3,254,787 L.L
A10BG03 ACTOS B Pioglitazone HCl - 30mg 30mg Tablet 2,484,765 L.L
A10BG03 ACTOS B Pioglitazone HCl - 15mg 15mg Tablet 1,243,054 L.L
S01EA05 ALPHAGAN P B Brimonidine tartrate - 1.5mg/ml 0.15% Drops solution 999,819 L.L
S01EA05 ALPHAGAN P B Brimonidine tartrate - 1.5mg/ml 0.15% Drops solution 999,819 L.L
N06DA02 ARICEPT B Donepezil HCl - 10mg 10mg Tablet, film coated 3,776,197 L.L
S01EA05 ALPHAGAN P B Brimonidine tartrate - 0.1% 0.15% Drops solution 999,819 L.L
C02AB02 ALDOMET B Methyldopa - 250mg 250mg Tablet, coated 644,400 L.L
D07AC14 ADVANTAN B Methylprednisolone aceponate - 1mg/g 1mg/g Ointment 385,683 L.L
C02AB02 ALDOMET B Methyldopa - 500mg 500mg Tablet, coated 856,708 L.L
D07AC14 ADVANTAN B Methylprednisolone aceponate - 1mg/g 1mg/g Cream 385,683 L.L
M04AA03 ADENURIC B Febuxostat - 120mg 120mg Tablet, film coated 2,184,704 L.L
S01EC04 AZOPT B Brinzolamide - 10mg/ml 10mg/ml Drops suspension 499,909 L.L
M04AA03 ADENURIC B Febuxostat - 80mg 80mg Tablet, film-scored 2,127,111 L.L
J01CR02 AUGMENTIN B Amoxicillin (trihydrate) - 250mg/5ml, Clavulanic Acid (potassium) - 62.5mg/5ml 312.5mg/5ml Powder for suspension 542,912 L.L
B01AX05 ARIXTRA B Fondaparinux sodium - 2.5mg/0.5ml 2.5mg/0.5ml Injectable solution 5,341,774 L.L
A07EC02 ASACOL B Mesalazine - 400mg 400mg Tablet, enteric coated 5,895,437 L.L
B01AX05 ARIXTRA B Fondaparinux sodium - 7.5mg/0.6ml 7.5mg/0.6ml Injectable solution 12,004,668 L.L
M04AA03 ADENURIC B Febuxostat - 40mg 40mg Tablet, film coated 1,687,866 L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026